No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALXO240517C12500
- 0.45
- -0.80-64.00%
15min DelayClose May 17 15:59 ET
0.45High0.45Low
0.45Open1.25Pre Close1 Volume4 Open Interest12.50Strike Price45.00Turnover4770.92%IV9.25%PremiumMay 17, 2024Expiry Date1.71Intrinsic Value100Multiplier-1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.6999Delta0.0629Gamma4.70Leverage Ratio-40.5498Theta0.0000Rho3.29Eff Leverage0.0004Vega
Intraday
- 5D
- 1D
News
Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares
ALX Oncology(ALXO.US) Officer Sells US$191.34K in Common Stock
$ALX Oncology(ALXO.US)$ Officer Randolph Sophia sold 12,000 shares of common stock on May 13, 2024 at an average price of $15.9449 for a total value of $191.34K.Source: Announcement What is statement
ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...
Piper Sandler Sticks to Its Buy Rating for ALX Oncology Holdings (ALXO)
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)
ALX Oncology | 10-Q: Quarterly report
Comments
$ALX Oncology(ALXO.US$ ALX Oncology Reports Clinical Data From Ongoing Phase 1/2 Investigator-Sponsored Trial Of Evorpacept In Combination With R2 In Patients With Indolent And Aggressive R/R B-NHL
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well to...
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well to...
1
$ALX Oncology(ALXO.US$ $ALXO 7,370,690 Shares of Common StockPre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock We are offering 7,370,690 shares of our common stock, par value $0.001 per share (common stock) and, in lieu of common stock to certain investors, pre-funded warrants to
$Avalo Therapeutics(AVTX.US$
Poor Performance So Far
Over the past few weeks, we have seen a lot of unusual activity in this ticker symbol. If there is anyone out there who knows why activity has picked up in AVTX, then please enlighten me.
Over the past few years, putting money into this company has been losing bet. Any stock that is in a long-term downtrend is usually something that I would stay away from.
Intriguing Technical Developmemts
Over the past few weeks,...
Poor Performance So Far
Over the past few weeks, we have seen a lot of unusual activity in this ticker symbol. If there is anyone out there who knows why activity has picked up in AVTX, then please enlighten me.
Over the past few years, putting money into this company has been losing bet. Any stock that is in a long-term downtrend is usually something that I would stay away from.
Intriguing Technical Developmemts
Over the past few weeks,...
+4
9
3
Read more